Live Breaking News & Updates on International Society Of Atopic Dermatitis Annual

Evelo Biosciences, Inc.: Evelo Biosciences Presents Further Positive Data from Phase 1b Clinical Trial of EDP1815 in Atopic Dermatitis
-Meaningful improvements over placebo on clinical scores, including new data released on key IGA endpoints-
-Initiation of Phase 2 trial of EDP1815 in atopic dermatitis expected in 3Q 2021-
CAMBRIDGE, Mass., April 20, 2021for all 24 patients in the cohort, which is re-iterated in the presentation, together with new data on the Investigator Global Assessment (IGA) score.
The primary endpoint of the Phase 1b trial was safety and tolerability. As previously disclosed, EDP1815 was well tolerated, with no treatment-related adverse events of moderate or severe intensity and no serious adverse events. The full results reinforce the data released on January 20, 2021, demonstrating that treatment with EDP1815 resulted in clinically meaningful improvements in both patient- and physician-reported outcomes. At the day 70 follow-up visit, 31% mo ....

United Kingdom , Evelo Biosciences , Jessica Cotrone , Kostenloser Wertpapierhandel , Douglas Maslin , International Society Of Atopic Dermatitis Annual , International Society , Atopic Dermatitis Annual , Investigator Global Assessment , Eczema Area , Severity Index , Atopic Dermatitis , Body Surface Area , Pharmacology Physician , Immunology Clinical Lead , Private Securities Litigation Reform Act , Annual Report , ஒன்றுபட்டது கிஂக்டம் , ஏவேலோ உயிர் அறிவியல் , டக்ளஸ் மஸ்லின் , சர்வதேச சமூகம் , புலனாய்வாளர் உலகளாவிய மதிப்பீடு , அரிக்கும் தோலழற்சி பரப்பளவு , தீவிரம் குறியீட்டு , உடல் மேற்பரப்பு பரப்பளவு , மருந்தியல் மருத்துவர் ,